Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2020
Kevin McFarthing, Sue Buff, Gary Rafaloff, et al.
Journal of Parkinson s Disease (2020) Vol. 10, Iss. 3, pp. 757-774
Open Access | Times Cited: 119

Showing 1-25 of 119 citing articles:

Challenges in the diagnosis of Parkinson's disease
Eduardo Tolosa, Alícia Garrido, Sonja W. Scholz, et al.
The Lancet Neurology (2021) Vol. 20, Iss. 5, pp. 385-397
Open Access | Times Cited: 1005
Parkinson disease-associated cognitive impairment
Dag Aarsland, Lucia Batzu, Glenda M. Halliday, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 767
Progress towards therapies for disease modification in Parkinson's disease
Nirosen Vijiaratnam, Tanya Simuni, Oliver Bandmann, et al.
The Lancet Neurology (2021) Vol. 20, Iss. 7, pp. 559-572
Open Access | Times Cited: 239
Treatment Options for Motor and Non-Motor Symptoms of Parkinson’s Disease
Frank Church
Biomolecules (2021) Vol. 11, Iss. 4, pp. 612-612
Open Access | Times Cited: 169
Alzheimer's and Parkinson's disease therapies in the clinic
Puja Chopade, Neha Chopade, Zongmin Zhao, et al.
Bioengineering & Translational Medicine (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 96
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update
Kevin McFarthing, Gary Rafaloff, Marco A. S. Baptista, et al.
Journal of Parkinson s Disease (2022) Vol. 12, Iss. 4, pp. 1073-1082
Open Access | Times Cited: 94
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update
Kevin McFarthing, Susan Buff, Gary Rafaloff, et al.
Journal of Parkinson s Disease (2023) Vol. 13, Iss. 4, pp. 427-439
Open Access | Times Cited: 54
The Emerging Role of the Lysosome in Parkinson’s Disease
Alba Navarro-Romero, Marta Montpeyó, Marta Martínez‐Vicente
Cells (2020) Vol. 9, Iss. 11, pp. 2399-2399
Open Access | Times Cited: 101
The Prion-Like Spreading of Alpha-Synuclein in Parkinson’s Disease: Update on Models and Hypotheses
Asad Jan, Nádia Pereira Gonçalves, Christian B. Vægter, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 15, pp. 8338-8338
Open Access | Times Cited: 77
Green Tea Epigallocatechin-3-gallate (EGCG) Targeting Protein Misfolding in Drug Discovery for Neurodegenerative Diseases
Priscila Baltazar Gonçalves, Ana Carolina Rennó Sodero, Yraima Cordeiro
Biomolecules (2021) Vol. 11, Iss. 5, pp. 767-767
Open Access | Times Cited: 73
Probiotics for Parkinson's disease: Current evidence and future directions
Ai Huey Tan, Jia Wei Hor, Chun Wie Chong, et al.
JGH Open (2020) Vol. 5, Iss. 4, pp. 414-419
Open Access | Times Cited: 70
Virtual exam for Parkinson’s disease enables frequent and reliable remote measurements of motor function
Maximilien Burq, Erin Rainaldi, King Chung Ho, et al.
npj Digital Medicine (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 63
Reappraisal of metabolic dysfunction in neurodegeneration: Focus on mitochondrial function and calcium signaling
Pooja Jadiya, Joanne F. Garbincius, John W. Elrod
Acta Neuropathologica Communications (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 58
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update
Kevin McFarthing, Gary Rafaloff, Marco A. S. Baptista, et al.
Journal of Parkinson s Disease (2021) Vol. 11, Iss. 3, pp. 891-903
Open Access | Times Cited: 56
The role of lysosomal cathepsins in neurodegeneration: Mechanistic insights, diagnostic potential and therapeutic approaches
Alice Drobny, Susy Prieto Huarcaya, Jan Philipp Dobert, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2022) Vol. 1869, Iss. 7, pp. 119243-119243
Open Access | Times Cited: 52
Functional brain networks in the evaluation of patients with neurodegenerative disorders
Matej Perovnik, Tomaž Rus, Katharina A. Schindlbeck, et al.
Nature Reviews Neurology (2022) Vol. 19, Iss. 2, pp. 73-90
Closed Access | Times Cited: 51
In Silico Molecular Docking Analysis of Karanjin against Alzheimer’s and Parkinson’s Diseases as a Potential Natural Lead Molecule for New Drug Design, Development and Therapy
Charles Gnanaraj, Mahendran Sekar, Shivkanya Fuloria, et al.
Molecules (2022) Vol. 27, Iss. 9, pp. 2834-2834
Open Access | Times Cited: 50
Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial
Johannes Levin, Nand Sing, Sue Melbourne, et al.
EBioMedicine (2022) Vol. 80, pp. 104021-104021
Open Access | Times Cited: 49
Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies
Sindhu Menon, Sabrina E.M. Armstrong, Amir Mohammad Hamzeh, et al.
Frontiers in Neurology (2022) Vol. 13
Open Access | Times Cited: 45
Intranasal delivery of full-length anti-Nogo-A antibody: A potential alternative route for therapeutic antibodies to central nervous system targets
Daphne Correa, Myriam I. Scheuber, Huimin Shan, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 4
Open Access | Times Cited: 23
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update
Kevin McFarthing, Sue Buff, Gary Rafaloff, et al.
Journal of Parkinson s Disease (2024) Vol. 14, Iss. 5, pp. 899-912
Open Access | Times Cited: 13
Dietary Interventions in Parkinson’s Disease
Indy van der Berg, Sabine Schootemeijer, Karin Overbeek, et al.
Journal of Parkinson s Disease (2024) Vol. 14, Iss. 1, pp. 1-16
Open Access | Times Cited: 10
Therapeutic Role of Heterocyclic Compounds in Neurodegenerative Diseases: Insights from Alzheimer’s and Parkinson’s Diseases
Nidhi Puranik, Minseok Song
Neurology International (2025) Vol. 17, Iss. 2, pp. 26-26
Open Access | Times Cited: 1
A Practical Approach to Early-Onset Parkinsonism
Giulietta Riboldi, Emanuele Frattini, Edoardo Monfrini, et al.
Journal of Parkinson s Disease (2021) Vol. 12, Iss. 1, pp. 1-26
Open Access | Times Cited: 45
Prevalence of Prodromal Symptoms of Parkinson’s Disease in the Late Middle-Aged Population
Dareia S. Roos, Martin Klein, Dorly J. H. Deeg, et al.
Journal of Parkinson s Disease (2022) Vol. 12, Iss. 3, pp. 967-974
Open Access | Times Cited: 35
Page 1 - Next Page

Scroll to top